{"nctId":"NCT00191113","briefTitle":"Somatropin Treatment to Final Height in Turner Syndrome","startDateStruct":{"date":"1989-02"},"conditions":["Turner Syndrome"],"count":154,"armGroups":[{"label":"Control","type":"NO_INTERVENTION","interventionNames":["Drug: Ethinyl estradiol","Drug: Medroxyprogesterone acetate"]},{"label":"Humatrope","type":"EXPERIMENTAL","interventionNames":["Drug: Somatropin","Drug: Ethinyl estradiol","Drug: Medroxyprogesterone acetate"]}],"interventions":[{"name":"Somatropin","otherNames":["Humatrope","Growth hormone"]},{"name":"Ethinyl estradiol","otherNames":[]},{"name":"Medroxyprogesterone acetate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* girl with Turner syndrome\n* prepubertal, Tanner stage I breast\n* height velocity less than 6 cm/year and height less than or equal to the tenth percentile for sex and age in general population\n* at least 6 months (preferably 12 months) of accurate height measurements available for calculation of pre-study height velocity\n* if thyroxine deficient, to have received replacement therapy, and for six months prior to enrollment have had normal thyroid function tests\n\nExclusion Criteria:\n\n* prior treatment with growth hormone\n* presence of a Y component in karyotype with gonads in situ\n* diabetes mellitus","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"7 Years","maximumAge":"13 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population","description":"Value analyzed is change from baseline to the most mature height measurement available. The terms Standard Deviation Score (SDS) and National Center for Health Statistics (NCHS) were defined in baseline characteristics. Greater height SDS values indicate greater height; positive values of change from baseline indicate increased height.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.07"},{"groupId":"OG001","value":"0.97","spread":"0.07"}]}]}]},{"type":"PRIMARY","title":"Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Last Measurement After Attainment of Final Height","description":"SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS \\[NCHS\\] uses the NCHS US general female population reference height values for age (Kuczmarski RJ et al. 2000) as the population mean and standard deviation. Calculation of Height SDS is provided in Height SDS \\[Lyon\\] description (Baseline). Since data reported by Kuczmarski RJ et al provides US general female population standards, values of Height SDS \\[NCHS\\] for untreated patients with Turner syndrome tend to be below zero e.g, -2.0 to -4.0 SDS.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.30","spread":"0.07"},{"groupId":"OG001","value":"-2.25","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline, As-Treated Population","description":"Value analyzed is change from baseline to the most mature height measurement available. The terms Standard Deviation Score (SDS) and National Center for Health Statistics (NCHS) were defined in baseline characteristics. Greater height SDS values indicate greater height; positive values of change from baseline indicate increased height.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.08"},{"groupId":"OG001","value":"0.99","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Height (Centimeters [cm])","description":"Most mature measurement available, at or after attainment of Final Height.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.63","spread":"0.47"},{"groupId":"OG001","value":"148.52","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Abnormal Pure Tone Audiometry, Audiologist Assessment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Speech Audiometry, Audiologist Assessment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Impedance Tympanometry, Audiologist Assessment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hearing Loss, Audiologist Assessment","description":"Sensorineural Hearing Loss (SNHL)=air conduction threshold \\>20 dB HL and air-bone gap ≤10 dB HL; Conductive Hearing Loss (CHL)= air conduction threshold \\>20 dB HL, bone conduction threshold ≤20 dB HL and air-bone gap \\>10 dB HL; Mixed Hearing Loss (MHL) = evidence of SNHL as defined above and CHL as defined above, in the same ear; Unspecified Hearing Loss (UHL)= abnormal hearing with none of SNHL, CHL, or MHL present.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Fasting Glucose, Change From Baseline","description":"Change from core study baseline to addendum 2 maximum.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.495","spread":"2.455"},{"groupId":"OG001","value":"3.003","spread":"1.830"}]}]}]},{"type":"SECONDARY","title":"Maximum Fasting Glucose Value","description":"Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":"6.6"},{"groupId":"OG001","value":"85.2","spread":"10.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Abnormal Fasting Glucose Value","description":"Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Fasting Glucose=Fasting Glucose \\>=100 milligrams per deciliter (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Fasting Insulin Values","description":"Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"10.8"},{"groupId":"OG001","value":"9.7","spread":"9.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Abnormal Fasting Insulin Value","description":"Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Fasting Insulin = Fasting Insulin \\>=35 micro International Units per milliliter (uIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Fasting Glucose/Insulin Ratio Values","description":"Minimum measured value over addendum. In special cases an additional measurement is taken at 2 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":"6.0"},{"groupId":"OG001","value":"12.2","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Abnormal Fasting Glucose/Insulin Ratio Value","description":"Indicates if patient had any measured value below threshold of normality at any visit during addendum. Abnormal Fasting Glucose/Insulin Ratio = Fasting Glucose/Insulin Ratio \\<=4.5 milligrams per 10\\^-4 Units (mg/10\\^-4U).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Glycosylated Hemoglobin, Change From Baseline","description":"Change from core study baseline to addendum 2 maximum.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.215","spread":"0.077"},{"groupId":"OG001","value":"0.208","spread":"0.057"}]}]}]},{"type":"SECONDARY","title":"Maximum Glycosylated Hemoglobin","description":"Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.5"},{"groupId":"OG001","value":"5.0","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Abnormal Glycosylated Hemoglobin (HbA1c) Value","description":"Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Glycosylated Hemoglobin = HbA1c ≥6.8% (up until 11-May-1998); and then HbA1c ≥6.1% (from 19-May-1998 onwards).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":54},"commonTop":["Cold","Headache","Sore throat","Fever","Flu"]}}}